Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EPS (Weighted Average and Diluted): 2019-2025

Historic EPS (Weighted Average and Diluted) for Bicycle Therapeutics (BCYC) over the last 6 years, with Sep 2025 value amounting to -$0.85.

  • Bicycle Therapeutics' EPS (Weighted Average and Diluted) fell 14.86% to -$0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.62, marking a year-over-year decrease of 11.04%. This contributed to the annual value of -$2.90 for FY2024, which is 42.91% up from last year.
  • Bicycle Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.85 in Q3 2025, which was up 25.44% from -$1.14 recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of -$0.59 in Q3 2021 and a low of -$1.41 during Q2 2023.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.88 (2025), whereas its average is -$0.99.
  • As far as peak fluctuations go, Bicycle Therapeutics' EPS (Weighted Average and Diluted) slumped by 65.57% in 2022, and later spiked by 52.31% in 2024.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then slumped by 65.57% to -$1.01 in 2022, then decreased by 11.88% to -$1.13 in 2023, then surged by 33.63% to -$0.75 in 2024, then dropped by 14.86% to -$0.85 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.85 in Q3 2025, compared to -$1.14 in Q2 2025 and -$0.88 in Q1 2025.